ArticleBMB reports2026
Cereblon enhances hepatic hepcidin production through estrogen-related receptor gamma activation.
Article in BMB reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepcidin (encoded by the HAMP gene), produced primarily by hepatocytes, is the master regulator of systemic iron homeostasis. Its dysregulation contributes to various iron-related metabolic disorders. Cereblon (CRBN) has been implicated in metabolic regulation, while estrogen-related receptor gamma (ESRRG) is known to govern energy homeostasis and mitochondrial function. In this study, we demonstrate a novel CRBN-ESRRG signaling pathway that mediates endoplasmic reticulum (ER) stress-induced hepatic HAMP expression. In mice and primary hepatocytes exposed to tunicamycininduced ER stress, gene expression and biochemical analyses revealed significant increases in the transcript levels of hepatic Crbn, Esrrg, and Hamp. Correspondingly, hepcidin protein levels were elevated, accompanied by reduced serum iron levels and increased cellular iron levels, consistent with hepcidinmediated regulation of iron distribution. Overexpression of Crbn enhanced ESRRG expression and increased hepatic hepcidin production, while knockdown of either Crbn or Esrrg attenuated this response. Chromatin immunoprecipitation assays demonstrated enhanced recruitment of ESRRG to the Hamp promoter. Collectively, these findings identify a CRBN-ESRRG regulatory axis that drives hepatic HAMP expression under ER stress and suggest a potential therapeutic target for ER stress-associated metabolic and iron disorders. [BMB Reports 2026; 59(5): 291-298].
Indexed as
Identifiers
41937537PMC13220105What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.